Inhibition of GATA2-dependent transactivation of the *TSH β* gene by ligand-bound estrogen receptor α

Koji Nagayama, Shigekazu Sasaki, Akio Matsushita, Kenji Ohba, Hiroyuki Iwaki, Hideyuki Matsunaga, Shingo Suzuki, Hiroko Misawa, Keiko Ishizuka, Yutaka Oki, Jaeduk Yoshimura Noh¹ and Hirotoshi Nakamura

Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, 1-20-1 Handayama, Hamamatsu, Shizuoka 431-3192, Japan

¹Ito Hospital, 4-3-6 Jingumae, Shibuya-ku, Tokyo, 150-8308, Japan

(Correspondence should be addressed to S Sasaki; Email: sasakis@hama-med.ac.jp)

Abstract

Transcriptional repression of the TSH-specific β subunit (*TSH β*) gene has been regarded to be specific to thyroid hormone (tri-iodothyronine, T_3) and its receptors (TRs) in physiological conditions. However, *TSH β* mRNA levels in the pituitary were reported to decrease in the administration of pharmacologic doses of estrogen (17- β -estradiol, E_2) and increase in E_2 receptor (ER)- α null mice. Here, we investigated the molecular mechanism of inhibition of the *TSH β* gene expression by E_2 -bound E_2 -estrogen receptor 1 (E_2 -ER α). In kidney-derived CV1 cells, transcriptional activity of the *TSH β* promoter was stimulated by GATA2 and suppressed by THR β s and ER α in a ligand-dependent fashion. Overexpression of PIT1 diminished the E_2 -ER α -induced inhibition, suggesting that PIT1 may protect GATA2 from E_2 -ER α targeting by forming a stable complex with GATA2. Interacting surfaces

between ER α and GATA2 were mapped to the DNA-binding domain (DBD) of ER α and the Zn finger domain of GATA2. E_2 -dependent inhibition requires the ER α amino-terminal domain but not the tertiary structure of the second Zn finger motif in E_2 -ER α -DBD. In the thyrotroph cell line, T α T1, E_2 treatment reduced *TSH β* mRNA levels measured by the reverse transcription PCR. In the human study, despite similar free thyroxine levels, the serum TSH level was small but significantly higher in post- than premenopausal women who possessed no anti-thyroid antibodies ($1.90 \mu\text{U/ml} \pm 0.13 \text{ S.E.M.}$ vs $1.47 \mu\text{U/ml} \pm 0.12 \text{ S.E.M.}$, $P < 0.05$). Our findings indicate redundancy between T_3 -TR and E_2 -ER α signaling exists in negative regulation of the *TSH β* gene.

Journal of Endocrinology (2008) **199**, 113–125

Introduction

Thyrotropin (thyroid-stimulating hormone, TSH) is a heterodimer consisting of the TSH-specific β subunit (*TSH β*) and the chorionic gonadotropin α chain (CGA) that is common to luteinizing hormone (LH), follicle-stimulating hormone (FSH), and chorionic gonadotropin. Thyroid hormone (tri-iodothyronine, T_3)-mediated negative feedback of TSH production in the pituitary is a central mechanism of the pituitary–thyroid axis and is believed to be specific to T_3 at physiological concentrations. However, administration of pharmacologic doses of estrogen (17- β -estradiol, E_2) was known to augment the effect of thyroid hormone replacement to suppress *TSH β* and CGA mRNA (Wondisford 1996 and references therein). Indeed, E_2 inhibits the upregulation of *Tsh β* and *Cga* mRNA in the pituitary of hypothyroid rats (Franklyn *et al.* 1987). Bottner & Wuttke (2005) and Bottner *et al.* (2006) reported that ovariectomy increased pituitary *TSH β* mRNA levels and that this elevation was abolished by 17 β - E_2 -3-benzoate treatment.

Boado *et al.* (1983) showed that E_2 benzoate induced a marked depression of intrapituitary TSH. Sekulic *et al.* (1998) demonstrated that E_2 treatment reduced the number of *TSH β* -positive cells in the rat pituitary.

There are two types of estrogen receptors (ERs), ER α and ER β . In the anterior lobe of the pituitary, ER α is the major receptor (Kuiper *et al.* 1996, Pelletier *et al.* 2000, Liu & Cui 2005) and is expressed in thyrotrophs as well as gonadotrophs (Stefaneanu *et al.* 1994, Gittoes *et al.* 1997). Interestingly, Scully *et al.* (1997) reported that, in the pituitary of ER α -deficient mice, mRNA levels for not only *Lh β* and *Fsh β* but also *Tsh β* and *Cga* were dramatically elevated. Compared with wild-type mice, the amount of mRNA for *Tsh β* and *Cga* in *Esr α* null mice increased by 3.20- and 4.36-fold respectively. Immunostaining using specific antibodies revealed that the number of *TSH β* - and CGA-positive cells also increased (Scully *et al.* 1997). These findings are similar to observations in mice devoid of all known T_3 receptors (TRs; Gothe *et al.* 1999). Although these observations suggest that E_2 suppresses *TSH β* expression via ER α , the molecular mechanism has not been clarified.

ER and TR belong to the nuclear hormone receptor superfamily and share a basic structure consisting of a receptor-specific amino-terminal domain (NTD), central DNA-binding domain (DBD), and carboxyl (C)-terminal ligand-binding domain (LBD; [Mangelsdorf et al. 1995](#)). In the promoter region of target genes whose transcription is enhanced by treatment with E₂ or T₃, ER homodimers and TR heterodimers formed with the retinoid X receptor (RXR) recognize the E₂-response element (ERE) and the T₃-response element (TRE) respectively. The tertiary structure of DBDs is maintained by two Zn finger motifs, and the amino acid sequences of the P- and D-boxes of DBD play critical roles in the differential recognition of ERE and TRE ([Umesono & Evans 1989](#)). E₂-bound ER (E₂-ER) and T₃-bound TR (T₃-TR) recruit coactivators such as members of the p160 family or CREB-binding protein (CREB)/p300, whose histone acetyl-transferase activities relax the chromatin structure and result in the enhancement of transcription ([Perissi & Rosenfeld 2005](#)). In addition, T₃-TR ([Ito & Roeder 2001](#)) and E₂-ER ([Zhang et al. 2005](#)) recruit TRAP220, a component of the TRAP/SRB/MED-containing cofactor complex of the RNA polymerase II holo-enzyme. In the absence of T₃, TR recruits co-repressors such as nuclear receptor co-repressor or the silencing mediator of retinoic acid and thyroid hormone receptors (SMRT). These co-repressors associate with histone deacetylases (HDACs), resulting in repression of transcription ([Perissi & Rosenfeld 2005](#)).

Of note, TR and ER have the potential to bind an identical half-site sequence, AGGTCA, although the number of spacing nucleotides between the half-sites and their orientations are different between TRE and ERE ([Mangelsdorf et al. 1995](#)); ERE can be recognized by the TR monomer, in addition to homodimer and heterodimer with RXR ([Klinge et al. 1997](#)). T₃-TR can also directly bind to ERE of the promoter for the progesterone receptor gene and stimulate its transcription ([Scott et al. 1997](#)). On the other hand, when TR and ER coexist, T₃-TR was reported to inhibit E₂-ER α -mediated transactivation of the promoters for the preproenkephalin gene ([Zhu et al. 1996](#), [Vasudevan et al. 2001b](#)) and the prolactin gene ([Pernasetti et al. 1997](#)), probably via sequestration of coactivators common to both receptors. Similar mutual inhibition has been reported between T₃-TR and other ligand-bound steroid hormone receptors ([Zhang et al. 1996](#)). Thus, the redundancy of DNA recognition and the common utilization of cofactors have been postulated to mediate crosstalk between the E₂-ER and T₃-TR signaling pathways ([Vasudevan et al. 2001a, 2002](#)).

In the mouse TSH β promoter, the DNA sequence between nt -271/-80 (corresponding to the sequence between nt -269/-78 in the human TSH β gene) was reported to be sufficient for maximal promoter activity in thyrotrophs ([Wood et al. 1990](#)). In this promoter region, there are binding sites for two transcription factors, PIT1 and GATA2 ([Haugen et al. 1996](#), [Gordon et al. 1997, 2002](#), [Dasen et al. 1999](#), [Charles et al. 2006](#)). Co-existence of PIT1 and

GATA2 in thyrotrophs is essential for the expression of the TSH β gene ([Gordon et al. 1997](#), [Dasen et al. 1999](#)). PIT1 is a pituitary-specific transcription factor expressed in somatotrophs, lactotrophs, and thyrotrophs. GATA2 is a subtype of the GATA family of transcription factors and binds with the GATA-responsive element (GATA-RE) through its Zn finger domain, which has high homology among all GATA family members ([Ferreira et al. 2005](#)). It was recently reported that TRAP220, which is a coactivator for liganded TR and ER, also functions as a coactivator for GATA2 and PIT1 ([Gordon et al. 2006](#)) and plays an important role in the transactivation of the TSH β gene ([Ito et al. 2000](#)). In addition, TRAP220 was reported to be a coactivator for GATA1 ([Stumpf et al. 2006](#)), transactivation by which is known to be inhibited by E₂-ER α ([Blobel et al. 1995](#), [Blobel & Orkin 1996](#)).

Using non-pituitary CV1 cells, we recently reported that T₃-TR β 2 represses the expression of the TSH β gene driven by GATA2 and PIT1 through interference of GATA2-induced transactivation, and that, contrary to the previous reports, the negative TRE (nTRE; [Wondisford et al. 1989](#)) and negative regulatory elements (NRE; [Sasaki et al. 1999](#)) were not required ([Matsushita et al. 2007](#)). The reporter assay using CV1 cells provides an ideal experimental platform to investigate the difference between positive and negative regulation by T₃, since this cell line is one of those most frequently used for the study of positive regulation ([Nakano et al. 2004](#)). We found that THRB-DBD directly interacts with the Zn finger domain of GATA2 (GATA2-Zf) and that T₃-TR targets TRAP220, which functions as a coactivator for GATA2 in the context of the TSH β promoter ([Matsushita et al. 2007](#)). Reflecting T₃-specificity *in vivo*, ligand-bound retinoic acid receptor, vitamin D receptor, RXR, or peroxisome proliferator-activated receptor γ 2 all did not exhibit negative regulation of the TSH β promoter in our experimental system ([Nakano et al. 2004](#)). Unexpectedly, however, E₂-ER α exhibited significant suppression of the TSH β promoter although the magnitude of suppression ($39.4\% \pm 4.5$ S.E.M.) was less than that of T₃-TR β 2 ($64.1\% \pm 2.6$ S.E.M.; [Nakano et al. 2004](#)). Here, we report that, in the negative regulation of the TSH β gene, there is a redundancy between E₂-ER α - and T₃-TR-mediated signaling pathways.

Materials and Methods

Plasmid construction

We recently found that not only T₃-TR ([Tillman et al. 1993](#), [Maia et al. 1996](#)) but also E₂-ER α have a tendency to suppress firefly luciferase-based reporter gene (data not shown). Thus, we employed the CAT-based reporter system. The TSH β -CAT reporter gene was constructed by fusing the human TSH β promoter (nt. -128/+37) with the CAT reporter gene, whose backbone lacks the pUC-derived AP-1 site ([Sasaki et al. 1999](#), [Nakano et al. 2004](#)). TSH β -D4-CAT was reported previously ([Matsushita et al. 2007](#)). The DNA fragment encompassing the promoter region for TSH β gene

(nt. 615/129) was amplified using PCR from human genomic DNA as template and subcloned into EcoRI site in *TSH β -CAT* to generate *TSH β (615/+37)-CAT*. In *TSH β -M1-CAT*, the putative nTRE/NRE remained intact (data not shown). The expression plasmids for mouse *Gata2* (pCDNA3-mGATA2), human *PIT1* (pCB6⁺-hPit1), wild-type human *TR β 1* (pCMX-hTR β 1), *TR β 1*-deletion mutants (pCI-C1 and C2), wild-type rat *Tr β 2* (pCMX-rTR β 2), and human *ER α* were described previously (Nakano *et al.* 2004). The deletion mutants of human *ER α* (Δ 170 and Δ 247) and mutant *ER α* such as C205S, C221G, and C240S were generated from wild-type *ER α* using standard subcloning techniques or a site-directed mutagenesis kit (Stratagene). The plasmid expressing the recombinant protein of the GATA2 Zn finger domain (GATA2-Zf) combined with glutathione-S-transferase (GST), pGEX-4T-1-GATA2-Zf, was described elsewhere (Matsushita *et al.* 2007). All constructs were confirmed by DNA sequencing.

Cell culture and transient transfection

CV1 cells were grown in monolayers and cultured at 37 °C under CO₂/air (1:19) in Dulbecco's modified Eagle's medium (DMEM) containing 10% dextran-charcoal-stripped fetal bovine serum (10% DCC serum), penicillin G (100 units/ml), and streptomycin (100 µg/ml). T α T1 cells, a mouse thyrocyte cell line (Yusta *et al.* 1998), were seeded on Matrigel-coated plates (Becton Dickinson Labware, Bedford, MA, USA). The cells were maintained under the same conditions as CV1 cells. The CV1 cells were trypsinized and plated in 60 mm diameter dishes for 24 h before transient transfection using the calcium phosphate technique (Sasaki *et al.* 1995). The cells at a density of 10⁶ cells/plate were transfected with 0.6 µg of the expression plasmids for *Esr α* or *Thrb* along with 4.0 µg of the *Tsh β -Cat* reporter gene, 1.8 µg β -galactosidase expression vector pCH111 (a modified version of pCH110; Pharmacia LKB Biotechnology), 0.1 µg human *PIT1* expression vector (pCB6⁺-hPit1), and 0.4 µg mouse *Gata2* expression vector (pCDNA3-mGATA2), and the pCMX empty vector as carrier DNA (7.2 µg DNA per dish in total). After the cells were exposed to the calcium phosphate/DNA precipitates for 20 h, the medium was replaced with phenol red-free DMEM containing 5% (v/v) and the cells were allowed to grow for an additional 24 h with or without 1 µM E₂ or T₃. After incubation for an additional 24 h, the cells were harvested and CAT activity was measured as described previously (Sasaki *et al.* 1995). The transfection efficiency was normalized by β -galactosidase assay. For each CAT reporter assay, we performed transfection with CAT reporter gene driven by cytomegalovirus promoter (CMV-CAT; 40 ng/dish), the magnitude of which was adjusted to the value of 100. Immunoblotting with anti-ER α antibody (1:200, cat. sc-8002, Santa Cruz Biotechnology, Santa Cruz, CA, USA) was performed using a standard method described previously (Matsushita *et al.* 2007).

GST pull-down assay

Escherichia coli (DH5 α) transformed with pGEX-4T-1-GATA2-Zf were induced with 0.1 mM isopropyl-1-thio- β -galactopyranoside for 4 h. The *E. coli* pellet was sonicated and the fusion proteins were mixed with glutathione-sepharose beads (Amersham Pharmacia Biotech) for purification. Receptor proteins were translated *in vitro* using rabbit reticulocyte lysate (Promega Corp.) in the presence of ³⁵S-methionine. Radio-labeled receptors were incubated with GST protein fused to GATA2-Zf (GST-Zf) in the binding buffer (150 mM NaCl, 20 mM Tris-HCl (pH 7.5), 0.3% Nonidet P-40, 1 mM dithiothreitol, 0.5 mM phenylmethylsulfonyl fluoride, 2 µg/ml aprotinin and leupeptin) for 3 h at 4 °C. The precipitants were washed three times with the binding buffer. Bound protein was analyzed by 10% SDS-PAGE and visualized using the FLA-3000 autoradiography system (Fujifilm, Tokyo, Japan).

Gel shift assay

Oligonucleotides for vit-A2 consensus ERE (Scott *et al.* 1997; sense, 5'-AATTCGTCCAAAGTCAGGTCACAGTGAC-CTGATCAAAGTT-3'; antisense, 5'-AACTTTGATCAG-GTCACTGTGACCTGACTTTGGACGAATT-3') were labeled with γ ³²P-ATP using thyroxine (T₄)-polynucleotide kinase (Toyobo, Tokyo, Japan). The receptor proteins were translated *in vitro* using a TNT T7 quick-coupled transcription/translation system (Promega Corp). The radio-labeled probes and *in vitro*-translated receptors were incubated for 20 min at room temperature in 20 µl binding buffer containing 10 mM HEPES-NaOH (pH 7.9), 50 mM KCl, 0.1 mM EDTA, 10% glycerol, 0.5 mM dithiothreitol, and 0.1 mg/ml poly (di-dC). The DNA-protein complexes were resolved on 5% polyacrylamide gels at 150 V for 1.5 h. Gels were dried and visualized using the FLA-3000 autoradiography system.

RNA isolation and real-time reverse transcription-PCR (RT-PCR)

T α T1 cells cultured in 10% DCC serum were incubated in the presence of 1 µM E₂ or T₃ for 48 h. The cells were harvested and total RNAs were purified by the acid guanidium thiocyanate-phenol-chloroform extraction method (Kawai *et al.* 2004). For the first-strand cDNA synthesis, 2 µg total RNA were mixed with random hexanucleotides and 200 units Moloney murine leukemia virus reverse transcriptase (Invitrogen Corp). The cDNA for *TSH β* was amplified with the forward primer (5'-GGCAAACGTGTTTCTTCCCAA-3') and the reverse primer (5'-TCTGTGGCTTGGTGCAG-TAG-3'). The cDNA for glyceraldehyde-3-phosphate dehydrogenase (*GAPDH*) was amplified with the forward primer (5'-TGAACGGGAAGCTCACTGG-3') and the reverse primer (5'-TCCACCACCCTGTTGGCTGTA-3'). PCR amplification was carried out using a DNA thermal cycler (Takara Bio Inc., Shiga, Japan) under the following

conditions: denaturation at 95 °C for 1 min, annealing at 62 °C for 1 min, extension at 72 °C for 2 min, and the final extension at 72 °C for 4 min. We determined the cycle number for each primer set so that the specific product was amplified during the exponential phase of the amplification. Based on preliminary studies (data not shown), 27 cycles were employed for the amplification of *TSH β* and *GAPDH* cDNA. The PCR products were subjected to electrophoresis on a 1.4% agarose gel and stained with ethidium bromide. Using the SYBR Green I kit and Light Cycler (Roche Diagnostics), precipitated DNA was quantified by real-time PCR using the primers mentioned above. The thermal cycling conditions were 10 min at 95 °C, followed by 27 cycles of 10 s at 95 °C for denaturing, 10 s at 62 °C for annealing, and 7 s at 72 °C for extension. PCR signals were analyzed using Light Cycler software Ver. 3.5 (Roche Diagnostics).

Measurement of serum TSH, free T₄, and E₂ in pre- and postmenopausal women

Among female patients who visited Ito Hospital in May 2004, 134 subjects with simple goiter or thyroid nodule(s) and no thyroid autoantibodies against thyroglobulin, thyroid peroxidase, or TSH receptor were extracted. They were divided into 62 premenopausal women and 72 postmenopausal women. The premenopausal group consisted of women between 30 and 50 years old (37.35 ± 5.40 years old) and their serum E₂ levels were all higher than 20 pg/ml. The postmenopausal group included women between 50 and 70 (59.29 ± 4.70) years old with serum E₂ levels lower than 20 pg/ml. TSH and free T₄ were measured with Roche ECLusys kit (Roche) and E₂ with electro chemiluminescence immunoassay (SRL, Tachikawa, Japan).

Statistical analysis

Each experiment was performed in duplicate more than three different times and each result is expressed as the mean $\pm$ S.E.M. Using StatView 4.0 software (Abacus Concepts Inc., Berkeley, CA, USA), we examined statistical significance in Figs 6 and 7 by Mann–Whitney *U* test. All other statistical analyses were performed using one-way ANOVA followed by Fisher's protected least significant difference test. $P < 0.05$ was considered significant.

Results

TSH β promoter activity is inhibited by not only T₃-TR β 2 but also E₂-ER α

To explore the molecular mechanism underlying the E₂-dependent inhibition of the *TSH β* gene expression, we carried out a reporter assay using *TSH β -CAT* (Fig. 1A), in which the human *TSH β* promoter (nt. 128/+37) is fused to the *CAT* reporter gene. In accordance with previous reports

(Gordon *et al.* 1997, Dasen *et al.* 1999), co-expression of PIT1 and GATA2 transactivated the *TSH β* promoter in CV1 cells (Fig. 1B, lane 2). This activity was significantly repressed by not only T₃-TR β 2 but also E₂-ER α (lanes 2, 4, and 6). When cognate receptors were co-expressed with PIT1 and GATA2, T₃ and E₂ inhibited transcription by $64.1\% \pm 2.6$ S.E.M. (lanes 3 and 4) and $39.4\% \pm 4.5$ S.E.M. (lanes 5 and 6) respectively. E₂-ER α -induced repression depended on the E₂ concentration (Fig. 1C) and the expression level of ER α (Fig. 1D). The inhibition of the *TSH β* promoter by E₂-ER α was observed in HeLa and 293T cells (data not shown). We also examined the effect of E₂-ER α on the *TSH β* (−615/+37)-*CAT* reporter gene, which has longer *TSH β* promoter encompassing nt. −615/+37, and found again that the transcriptional activity in CV1 cells was stimulated by PIT1 and GATA2, and significantly decreased by 1 μ M E₂ (Fig. 1E).

Overexpression of PIT1 relieves E₂-dependent inhibition of the TSH β gene and E₂-ER α targets GATA2-induced transactivation

We tested the effect of PIT1 overexpression on the negative regulation of the *TSH β* promoter by E₂-ER α . As shown in Fig. 2A, inhibition by E₂-ER α was abolished by increased levels of PIT1, suggesting that a large amount of PIT1 antagonizes the E₂-ER α -dependent inhibition of the *TSH β* gene. We recently found that deletion of a short sequence between GATA-REs and the TATA-box in the *TSH β* promoter (nt. 82/52; Fig. 1A) enabled GATA2 alone to transactivate without PIT1 (Matsushita *et al.* 2007), and we designated this deleted sequence as the suppressor region (SR). The construct *TSH β -M1-CAT* (Fig. 2B, left panel) in which SR was deleted was activated by GATA2 alone, and this activity was inhibited by E₂-ER α (Fig. 2B, right panel). GATA2 alone without PIT1 transactivated two other reporter constructs, *TSH β -D4-CAT*, in which nTRE/NRE in *TSH β -M1-CAT* was mutated (Matsushita *et al.* 2007), and CGA-CAT, which possesses a functional GATA-RE (Steger *et al.* 1994). Again, E₂-ER α repressed the GATA2-induced transactivation of *TSH β -D4-CAT* and CGA-CAT by $53.1\% \pm 1.9$ S.E.M. and $30.5\% \pm 6.2$ S.E.M. respectively (data not shown). Collectively, transactivation by GATA2 alone was sufficient to mediate negative regulation by E₂-ER α and PIT1 antagonized this inhibition.

The Zn finger domain of GATA2 directly interacts with TR and ER α in vitro

The amino acid sequence of the Zn finger domain of GATA2 (GATA2-Zf), but not the N- or C-terminal region, has high homology with that of GATA1 (Fig. 3A), and both GATAs are known to transactivate the same GATA-RE. In addition, E₂-ER α was reported to inhibit GATA1-induced transactivation (Blobel *et al.* 1995). As predicted, GATA1-induced transactivation of *TSH β -CAT* was also repressed by

Figure 1 Effect of E₂-ERα on the *TSHβ* promoter activity stimulated by PIT1 and GATA2. (A) Schematic of the *TSHβ*-CAT. The binding sites for PIT1 and GATA2, suppressor region (SR), TATA box, and reported nTRE/NRE are indicated as boxes. (B) Using the calcium phosphate method, the expression plasmids for ERα or TRβ2 (0.6 μg) were co-transfected with *TSHβ*-CAT (4.0 μg), PIT1 (0.1 μg), and GATA2 (0.4 μg) into CV1 cells in the absence or presence of 1 μM E₂ or T₃ respectively. After incubation for 24 h, the cells were harvested and the CAT activity was measured. The CAT activity of CMV-CAT is represented as 100%. The data are shown as the mean ± S.E.M. of at least six individual experiments. **P*<0.05; ***P*<0.01; #*P*<0.05 versus PIT1 and GATA2. (C) *TSHβ*-CAT was co-transfected with PIT1, GATA2, and ERα into CV1 cells in the presence of 0–1 μM E₂. The CAT activity of CMV-CAT is represented as 100% **P*<0.05; ***P*<0.01. (D) Increasing amounts of the ERα expression plasmid (0–0.6 μg/6 cm dish) were co-transfected with *TSHβ*-CAT (4.0 μg) and the expression plasmid for PIT1 (0.1 μg) and GATA2 (0.4 μg) into CV1 cells. The magnitude of CAT activity without E₂ was divided by that with E₂ (1 μM) to calculate the fold repression. The results are shown as the means ± S.E.M. from six independent experiments. **P*<0.05; ***P*<0.01. (E) The expression plasmids for ERα (0.6 μg) were co-transfected with *TSHβ* (−615/+37)-CAT (4.0 μg), PIT1 (0.1 μg), and GATA2 (0.4 μg) into CV1 cells in the absence or presence of 1 μM E₂. All results in (E) are shown as means ± S.E.M. for eight independent experiments. **P*<0.05. The CAT activity of CMV-CAT is represented as 100%.

E₂-ERα (Fig. 3B). While C-terminal finger of GATA1 directly recognizes the GATA-RE, the N-terminal finger is known to interact with Friend of GATA (FOG) 1 and 2 that are the strong co-repressor for the GATA family transcription factors. We reported (Matsushita *et al.* 2007) that transactivation by a mutant GATA2, GATA2-C295A (Fig. 3A), which has an amino acid substitution from cysteine to alanine at codon 295 of the N-terminal Zn finger, was resistant to the inhibition by T₃-TRβ2. The finding that the basal transcription by C295A was significantly higher than that by empty vector (Fig. 3C) indicates that the overall structure as functional GATA2 is partly preserved in this mutant. However, transactivation

induced by GATA2-C295A was not inhibited by E₂-ERα. These findings indicate that interaction between GATA2-Zf and ERα is essential to E₂-ERα-mediated inhibition. Using the GST fusion protein with GATA2-Zf (GST-Zf, Fig. 3A), we tested the direct interaction between ERα and GATA2-Zf *in vitro*. As reported previously (Matsushita *et al.* 2007), GST-Zf interacted with TRβ1 (Fig. 3D, upper panel) but not the luciferase protein (lower panel). In an E₂-independent manner, GST-Zf also bound to radio-labeled full-length ERα (Fig. 3D, middle panel). As shown in Fig. 3E, the mutant ERαs N2 and Δ247, which lacked DBD, did not interact with GST-Zf, suggesting that ERα-DBD binds to GATA2-Zf as in the case of THRβ-DBD.

Figure 2 Roles of PIT1 in the negative regulation of *TSH β* gene expression by E₂-ER α (A) *TSH β* -CAT (4.0 μ g) was transfected into CV1 cells together with the expression plasmids for PIT1 (0.1–0.4 μ g), GATA2 (0.4 μ g), and ER α (0.6 μ g) in the absence or presence of 1 μ M E₂ (left panel). The fold repression (right panel) was calculated from CAT activity without E₂ divided by that with 1 μ M E₂. (B) Schematic of *TSH β* -M1-CAT (left panel). The suppressor region (SR) was deleted in this construct. *TSH β* -M1-CAT was co-transfected with the expression plasmids for ER α , GATA2 into CV1 cells in the absence or presence of 1 μ M E₂. The results are shown as means $\pm$ S.E.M. from six experiments. **P* < 0.05.

*The E₂-ER α -induced inhibition of the *TSH β* promoter does not require the second Zn finger motif*

P- and D-boxes and the zinc finger structure in DBD are critical constituents that determine receptor specificity in ligand-dependent positive regulation (Mangelsdorf *et al.* 1995). To investigate the involvement of these motifs in the negative regulation of the *TSH β* gene, we generated three mutant ER α s: C205S in the P-box and C221G and C240S in the stem of the second Zn finger (Fig. 4A, upper panel). Western blot analysis with an anti-ER α antibody indicated that expression levels of these mutants in CV1 cells were comparable (lower panel). As predicted, these mutants lost DNA-binding affinity as demonstrated by gel shift assay with vitellogenin A2-derived ERE (vit-A2-ERE; Scott *et al.* 1997; Fig. 4B), and failed to activate the *ERE-tk-CAT* reporter gene, in which vit-A2 ERE is fused to the *CAT* reporter gene driven by the thymidine kinase (tk) promoter (Fig. 4C, left panel). As shown in the right panel of Fig. 4C, negative regulation of the *TSH β* promoter induced by PIT1 and GATA2 was abolished in C205S and C221G. The findings that C205S and C221G directly interacted with GATA2-Zf (Fig. 4D) suggest that physical interaction of ER α -DBD with GATA2 is not sufficient for inhibition by E₂-ER α . Unexpectedly, another mutant ER α , C240S (Fig. 4A) preserved E₂-induced negative regulation of the *TSH β* gene (Fig. 4C) as well as *in vitro* binding with GATA2-Zf (Fig. 4D), suggesting that the tertiary structure of the second Zn finger motif, which is necessary for ERE recognition, is dispensable for inhibition of the *TSH β* gene.

*The E₂-induced inhibition of the *TSH β* promoter requires ER α -NTD*

We previously reported that TR β 1-NTD is dispensable for the negative regulation of the *TSH β* promoter (Nakano *et al.* 2004). We wanted to compare the function of NTDs of ER α . In contrast to TR β 1, the ER α -NTD truncation mutant Δ 170 (Fig. 5A, middle upper panel) did not inhibit but rather stimulated the transcription (right panel), although it mediated positive regulation (left panel). These data suggest that ER α -NTD is critical for inhibition by E₂. As predicted, ER α (Δ 247), which lacks the DBD, did not exhibit ligand-dependent transactivation or inhibition. The expression levels of mutant ER α s were comparable (middle lower panel).

As shown in Fig. 5B, the amino acid sequences between ER α and ER β were conserved in their DBD (96%) and LBD (58%) but not in NTDs (McInerney *et al.* 1998). We found that repression of the *TSH β* promoter by E₂-ER β was impaired and the effect of E₂ was not statistically significant (Fig. 5C). To exclude the possibility that ER α -LBD may communicate with the NTD of the same ER α molecule, we tested the function of the chimeric ER α , β N α C, in which the NTD was substituted with that of ER α (Yi *et al.* 2002; Fig. 5B). Again, β N α C failed to mediate E₂-dependent repression (Fig. 5D). Western blotting with an antibody against the C-terminal region of ER α indicated that expression levels of wild-type ER α and β N α C were comparable (Fig. 5E). Together, these findings indicate that the ER α -NTD has an important role in E₂-dependent inhibition.

*Effect of E₂ on the expression of the *TSH β* gene in thyrotroph cell line T α T1*

Serum E₂ concentration is known to influence not only the level of T₄-binding globulin (TBG; Surks & Sievert 1995) but also the production of T₃ and T₄ from the thyroid gland (Furlanetto *et al.* 1999, Sosic-Jurjevic *et al.* 2005, Alotaibi *et al.* 2006, Lima *et al.* 2006). Using cultured thyrotroph cell line T α T1 (Yusta *et al.* 1998), we studied the direct effect of E₂ on the *TSH β* mRNA level. When *TSH β* mRNA was detected by conventional RT-PCR, not only T₃ but also E₂ reduced the intensity of the *TSH β* mRNA band (Fig. 6A). We further measured *TSH β* mRNA expression by real-time quantitative RT-PCR (Fig. 6B). Although the magnitude was smaller than that for T₃, E₂ treatment also significantly reduced the level of *TSH β* mRNA (67.2% $\pm$ 12.1 S.E.M. vs 49.5% $\pm$ 14.9 S.E.M., *P* < 0.05). The magnitudes of suppression were correlated to those from the reporter assay using *TSH β* -CAT (Fig. 1B).

Comparison of serum TSH levels between pre- and postmenopausal women

To evaluate the clinical significance of E₂ effects on serum TSH, we compared the serum TSH level of 72 postmenopausal women with that of 62 premenopausal women,

Figure 3 The interaction between GATA2-Zf and ER α -DBD. (A) Schematic of GATA1, GATA2, GATA2-C295A, and GST-Zf. The boundaries of the Zn finger region were deduced by comparison with chicken GATA1 reported by Boyes *et al.* (1998). The homology of amino acids among GATA1 relative to GATA2 is indicated as a percentage in the boxes. In GST-Zf, GST protein was fused to GATA2-Zf. (B) The transactivation of TSH β -CAT by GATA1 and GATA2 was suppressed by E₂-ER α . The expression plasmids for mouse GATA1 or 2 (0.4 μ g) were transfected together with that for PIT1 (0.1 μ g) into CV1 cells. The results are shown as the means $\pm$ S.E.M. from six independent experiments. (C) The expression plasmids for mouse GATA2 or GATA2-C295A (0.4 μ g) were transfected into CV1 cells under the same conditions as Fig. 1B. The results are shown as the means $\pm$ S.E.M. from six independent experiments. The magnitude of the CAT activity stimulated by wild-type GATA2 and PIT1 was taken as 100%. * P < 0.05; ** P < 0.05 versus reporter alone (first lane). (D) GST-Zf was incubated with ³⁵S-labeled TR β 1 or ER α in the presence or absence of 1 μ M T₃ or E₂ respectively. ³⁵S-labeled luciferase protein was utilized as a control. Arrowheads indicate ³⁵S-labeled TR β 1 (upper panel), ER α (middle panel), and luciferase protein (lower panel). luc: luciferase protein. I and B indicate input and bound respectively. (E) ³⁵S-labeled wild-type ER α or its deletion constructs were incubated with GST-Zf. GST-Zf interacted with full-length ER α , Δ 170, and N1 but not with Δ 247 or N2, which lack DBD. I and B indicate input and bound respectively.

who visited Ito Hospital because of simple goiter or thyroid nodule(s) in May 2004 and none had any thyroid autoantibodies. Because age-related decline in thyroid function is not noticeable until the eighth decade of life (Mariotti *et al.* 1993), we recruited female subjects with ages up to 70 years old as the postmenopausal population. As predicted, the serum E₂ levels in postmenopausal females were very low (Fig. 7, left panel). Although there was no difference in the free T₄ concentrations (middle panel), the serum TSH level of the postmenopausal group was significantly higher than that of the premenopausal group (right panel).

Discussion

In the present study, we demonstrated that E₂-ER α inhibits transactivation of the TSH β gene through a mechanism similar to inhibition by T₃-TRs. We used reporter assay in the CV1 cell line, which is ideal for comparing the mechanism of ligand-dependent negative regulation of the TSH β gene with that of positive regulation (Nakano *et al.* 2004). Our findings imply that redundancy in the recognition of target genes exists not only in the positive regulation (Klinge *et al.* 1997, Scott *et al.* 1997) but also in the negative regulation of the TSH β gene. It was postulated that E₂-dependent inhibition of the

Figure 4 Mutation analysis of ER α -DBD. (A) Schematic of ER α -DBD (upper panel). Cysteines at codon 205 in the P-box and 221 and 240 in the stem of second Zn finger were substituted to serine (C205S), glycine (C221G), and serine (C240S). The expression levels of wild-type and mutant ER α s were comparable (lower panel). CV1 cells were transfected with the expression plasmids for wild-type or mutant ER α s. Whole cell extracts were fractionated by SDS-PAGE and subjected to western blot (WB) with anti-ER α antibody against the C-terminal region of ER α . (B) ³²P-radio-labeled vit-A2 ERE was incubated with *in vitro*-translated protein for wild-type or mutant ER α s. ERE, specific cold competitor. NS, non-specific cold oligo DNA. Arrow, specific binding of ER α ; arrowhead, nonspecific binding. (C) ERE-tk-CAT (left panel) was transfected into CV1 cells together with the expression plasmid for ER α in the presence or absence of 1 μ M E₂. CAT activity with 1 μ M E₂ was divided by that without E₂ to calculate fold activation. TSH β -CAT (right panel) was transfected into CV1 cells together with the expression plasmids for PIT1, GATA2, and wild or mutant ER α s as shown in Fig. 1B. CAT activity without E₂ was divided by that with 1 μ M E₂ to calculate fold repression. (D) ³⁵S-radio-labeled receptors were incubated with GST protein fused to GST-Zf and binding fractions were subjected to SDS-PAGE.

TSHβ gene was mediated via direct binding of ER α with the putative nTRE (Wondisford 1996). However, this is unlikely, because E₂-induced inhibition is preserved in the ER α mutant C240S, which fails to bind or activate canonical vit-A2-ERE (Fig. 4C). In agreement with this, E₂-ER α inhibited GATA2-induced transactivation of *TSHβ-D4-CAT*, which lacked a DNA sequence homologous to the half-site. Moreover, E₂-ER α repressed the activity of *TSHβ-M1-CAT* (Fig. 2B) and CGA-CAT stimulated by GATA2 alone (data not shown), suggesting that interference of GATA2-induced transactivation by E₂-ER α is the mechanism for inhibition of the *TSHβ* gene. This notion is further supported by the observation that transactivation by the mutant GATA2-C295A was resistant to E₂-ER α -induced suppression (Fig. 3C). ER α interacts directly with PIT1 (Ying *et al.* 1999), and these two transcription factors synergize in the transactivation of the prolactin gene in lactotrophs

(Chuang *et al.* 1997, Schaufele 1999), whose most important PIT1-binding site is located adjacent to the ERE (Nowakowski & Maurer 1994). However, current results indicate that E₂-ER α -dependent inhibition of the *TSHβ* promoter does not require PIT1 (Fig. 2B) and is rather crippled by the overexpression of this transcription factor (Fig. 2A).

Although the results of the transfection experiments as well as the cell culture studies are obtained with high pharmacological doses of E₂, the overall results were in accordance with our recent findings regarding the T₃-dependent inhibition of the *TSHβ* gene (Matsushita *et al.* 2007). The repression of GATA2-induced activation by E₂-ER α and T₃-TR may occur by a 'tethering mechanism' (Nissen & Yamamoto 2000, Herrlich 2001), where liganded nuclear receptors interfere with the activity of DNA-binding transcription factors through protein-protein interactions. In this kind of inhibition, redundancy among liganded

Figure 5 Involvement of NTD in the negative regulation of *TSHβ* gene by E₂-ERα. (A) In the presence of 1 μM E₂, expression plasmids for ERα or its mutants, Δ170 and Δ247 (middle upper panel) were transfected into CV1 cells together with the ERE-tk-CAT reporter gene (left panel) or TSHβ-CAT and the expression plasmids for PIT1 and GATA2 (right panel). **P* < 0.05 versus empty vector for receptor expression plasmids. The CAT activity with the ligand was divided by that without ligand to calculate fold activation (left panels). The CAT activity without ligand was divided by that with 1 μM ligand to calculate fold repression (right panels). The expression levels of wild-type and mutant ERαs were comparable (middle lower panel). The CV1 cells were transfected with the expression plasmid for wild-type or mutant ERαΔ170 and Δ247. Western blot (WB) was performed as Fig. 4A. (B) Schematic of ERα, ERβ and chimeric receptor βNαC. In βNαC, NTD of ERα is replaced with that of ERβ. The homology of amino acids among ERβ and βNαC relative to ERα is indicated as a percentage in the boxes. (C) The expression plasmid for ERα or ERβ was transfected into CV1 cells together with TSHβ-CAT and the expression plasmids for PIT1 and GATA2. **P* < 0.05 versus PIT1 and GATA2. (D) In the presence or absence of 1 μM E₂, the expression plasmid for ERα or βNαC was transfected into CV1 cells together with TSHβ-CAT and the expression plasmids for PIT1 and GATA2. CAT activity without E₂ was divided by that with E₂ (1 μM) to calculate the fold repression (right panel). The results are shown as means ± S.E.M. for eight separate experiments. **P* < 0.05. (E) Expression levels of wild-type ERα and βNαC were comparable. The CV1 cells were transfected with the expression plasmid for wild-type or βNαC and western blot with antibody against the C-terminal region of ERα was performed as Fig. 4A.

receptors has been reported. For example, E₂-ERα (Kalaitzidis & Gilmore 2005) and glucocorticoid (GC)-bound GC receptor (GR; McKay & Cidlowski 1999, De Bosscher *et al.* 2003) repress transactivation by the proinflammatory transcription factor NF-κB by interacting with it. Similarly, the transcriptional activity of AP-1 (typically the Jun/Fos heterodimer) is impaired by T₃-TR and GC-GR (De Bosscher *et al.* 2003).

Although the precise mechanism of how E₂-ERα inhibits the function of GATA2 in transactivation of the *TSHβ* gene is uncertain, the present analysis provides several insights. First,

the GST pull-down assay (Fig. 3E) indicated that DBD is essential for the interaction of ERα with GATA2-Zf as in the case of THRβs (Matsushita *et al.* 2007). Second, E₂-dependent inhibition does not require the tertiary structure of the second Zn finger motif in ERα-DBD, since E₂-dependent inhibition was preserved in the mutant ERα C240S (Fig. 4C), which contains a disrupted second Zn finger motif (Fig. 4A). Third, it should be noted that the mutant ERαs, C205S, and C221G, failed to inhibit E₂-dependent inhibition of the *TSHβ* gene (Fig. 4C), although both mutants can physically bind GATA2-Zf *in vitro*

Figure 6 Effect of E_2 on the expression of *TSHβ* mRNA in the cultured thyrotroph cell line, TαT1. (A) *TSHβ* mRNA isolated from TαT1 cells treated with 1 μM T_3 or 1 μM E_2 for 48 h and evaluated with RT-PCR. RT (-), PCR without reverse transcriptase. (B) *TSHβ* mRNA expression evaluated by real-time quantitative RT-PCR. The experiments were repeated five times. The amount of the PCR products was normalized with that of the *GAPDH* gene. The data are shown as means ± S.E.M. Statistical significance was determined by Mann-Whitney *U* test. * $P < 0.05$.

(Fig. 4D). The same results were obtained with the mutant TRβ2 G182E (Matsushita *et al.* 2007) and the mutant TRβ1 C127S and C145G (Nakano *et al.* 2004 and data not shown). Physical binding alone is not sufficient to mediate ligand-dependent inhibition, and subtle changes of amino acids on the surface of DBD may be functionally critical. Similar conclusions were made after analysis of mutant GR using circular dichroism (Tao *et al.* 2001).

GATA2-Zf interacts with multiple coactivators including CBP/p300 (Blobe *et al.* 1998, Hayakawa *et al.* 2004),

Figure 7 Elevation of serum TSH levels after menopause in women with simple goiter who possess no autoantibodies against thyroglobulin, thyroid peroxidase, or TSH receptor. The levels of E_2 (left panel), free T_4 (middle panel), and TSH (right panel) in 62 premenopausal women and 72 postmenopausal women are indicated. The data are shown as means ± S.E.M. Statistical significance was determined by Mann-Whitney *U* test. * $P < 0.05$; ** $P < 0.01$.

TRAP220 (Crawford *et al.* 2002, Gordon *et al.* 2006), and transcriptional repressors such as HDAC3 (Ozawa *et al.* 2001) and FOG 1 and 2 (Ferreira *et al.* 2005). ERα and TR share common coactivators including the p160 family (SRC1, TIF2/GRIP1, and AIB1/ACTR), CBP/p300, p300/CBP-associating factor (PCAF), and TRAP220. As in the case of T_3 -THRBs (Matsushita *et al.* 2007), overexpression of SRC-1, CBP, or PCAF did not show reproducible effects on the negative regulation of the *TSHβ* gene by E_2 -ERα (data not shown). TRAP220 is required for the expression of the *TSHβ* gene (Ito *et al.* 2000) and functions as a coactivator for GATA2 (Gordon *et al.* 2006), GATA1 (Stumpf *et al.* 2006), TR (Ito & Roeder 2001), and ERα (Zhang *et al.* 2005). TR (Ito & Roeder 2001) and ERα (Zhang *et al.* 2005) recognize an extended amino acid sequence encompassing two LXXLL motifs in TRAP220 with a specificity distinct from that of coactivators in the p160 family (Acevedo & Kraus 2003, Coulthard *et al.* 2003). We reported that dnTRAP220 (Yuan *et al.* 1998) relieved the T_3 -TR-dependent inhibition of the *TSHβ* promoter and that TRAP220 dissociated from this promoter after T_3 treatment of TαT1 cells (Matsushita *et al.* 2007). We found that the expression of the dnTRAP220 also abolished the E_2 -ERα-induced inhibition of the *TSHβ* gene (data not shown). Thus, TRAP220 may play a role in the inhibition of the *TSHβ* gene by E_2 -ERα and T_3 -TR.

We found that ERα-NTD plays an essential role in the repression of the *TSHβ* gene by E_2 (Fig. 5). This domain interacts directly with the p160 family (Lavinsky *et al.* 1998, Webb *et al.* 1998), p300 (Kobayashi *et al.* 2000), HDAC4 (Leong *et al.* 2005), and repressor of tamoxifen transcriptional activity (Norris *et al.* 2002). Although ERα-NTD may bind directly with LBD (Kraus *et al.* 1995, Metivier *et al.* 2000, *et al.* 2001) or regulate the interaction between the antagonist bound LBD and its co-repressor (Lavinsky *et al.* 1998), the βnαC data indicate that ERα-NTD has an intrinsic function to control the E_2 -dependent inhibition of the *TSHβ* gene. TRβ2-NTD was reported to have a strong T_3 -independent transactivation effect on TRE (Sjoberg & Vennstrom 1995) and also to regulate the interaction between LBD and SMRT (Yang & Privalsky 2001). A function unique to TRβ2-NTD may account for its stronger repression of the *TSHβ* gene than TRβ1 (Nakano *et al.* 2004). Importance of GR-NTD was also reported for ligand-dependent inhibition of AP-1 activity (Heck *et al.* 1994).

E_2 is known to have profound influence on the thyroid hormone system, including cell proliferation (Furlanetto *et al.* 1999), iodine uptake (Furlanetto *et al.* 1999, Alotaibi *et al.* 2006, Lima *et al.* 2006), thyroid peroxidase activity (Lima *et al.* 2006), de-iodinases (Lisboa *et al.* 2001, Wasco *et al.* 2003), or TBG (Gross *et al.* 1971, Surks & Sievert 1995, Arafah 2001). Altered thyroid hormone production and metabolism may mask the direct effect of E_2 on *TSHβ* expression. To exclude the influences of E_2 on T_3 and T_4 levels in the circulating blood, we measured *TSHβ* mRNA in TαT1 cells and found that E_2 significantly repressed the expression of *TSHβ* mRNA (Fig. 6). We studied serum

TSH levels in women with simple goiter or thyroid nodule(s), who had no thyroid autoantibodies. The TSH level was significantly higher in the postmenopausal than premenopausal population (Fig. 7). Since the age of the postmenopause group was between 50 and 70 years old, thyroidal deterioration due to aging is unlikely (Mariotti *et al.* 1993). A small but significant increase in the TSH level after menopause may be related to the decreased TSH suppression by E₂. Although free T₄ or serum E₂ data were not available, the NHANES III report (Hollowell *et al.* 2002) also showed that the TSH concentration tended to increase with age in female populations without thyroid autoantibodies. Surks & Hollowell (2007) have recently analyzed TSH frequency distribution curves in NHANES III and showed the progressive shift toward higher concentrations of TSH with age irrespective of thyroid antibodies. They say that an explanation for this shift to higher TSH ranges in elderly people is not apparent, but we consider that our finding in this study is one of the main factors.

Declaration of Interest

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding

This work was supported, in part, by a Health Sciences Research Grant to H N, and a Grant-in Aid for Scientific Research to S S and H N from the Ministry of Education, Culture, Sports, Science, and Technology in Japan.

Acknowledgements

We are grateful to the following researchers for providing the plasmids; Drs Kazuhiko Umesono (Kyoto University, Japan), Ronald M Evans (The Salk Institute, La Jolla, USA), Akihiro Sakurai (Shinshu University, Matsumoto, Japan), Masayuki Yamamoto (Tsukuba University, Tsukuba, Japan), Akira Kakizuka (Kyoto University, Kyoto, Japan), Takashi Nagaya (Nagoya University, Nagoya, Japan), Keita Tatsumi (Osaka University, Osaka, Japan), Mesut Muyan (University of Rochester Medical Center, Rochester, USA), and Leonard P Freedman (Memorial Sloan-Kettering Cancer Center, New York, USA). We also thank Dr P L Mellon (University of California, San Diego, CA, USA) for providing T α T1 cells and Dr Keiichi Itoi (Tohoku University, Japan) for the sequence information of the RT-PCR primers.

References

Acevedo ML & Kraus WL 2003 Mediator and p300/CBP-steroid receptor coactivator complexes have distinct roles, but function synergistically, during estrogen receptor α -dependent transcription with chromatin templates. *Molecular and Cellular Biology* **23** 335–348.
 Alotaibi H, Yaman EC, Demirpence E & Tazebay UH 2006 Unliganded estrogen receptor- α activates transcription of the mammary gland Na⁺/I⁻ symporter gene. *Biochemical and Biophysical Research Communications* **345** 1487–1496.
 Arafah BM 2001 Increased need for thyroxine in women with hypothyroidism during estrogen therapy. *New England Journal of Medicine* **344** 1743–1749.

Blobel GA & Orkin SH 1996 Estrogen-induced apoptosis by inhibition of the erythroid transcription factor GATA-1. *Molecular and Cellular Biology* **16** 1687–1694.
 Blobel GA, Sieff CA & Orkin SH 1995 Ligand-dependent repression of the erythroid transcription factor GATA-1 by the estrogen receptor. *Molecular and Cellular Biology* **15** 3147–3153.
 Blobel GA, Nakajima T, Eckner R, Montminy M & Orkin SH 1998 CREB-binding protein cooperates with transcription factor GATA-1 and is required for erythroid differentiation. *PNAS* **95** 2061–2066.
 Boado R, Ulloa E & Zaninovich AA 1983 Effects of oestradiol benzoate on the pituitary–thyroid axis of male and female rats. *Acta Endocrinologica* **102** 386–391.
 De Bosscher K, Vanden Berghe W & Haegeman G 2003 The interplay between the glucocorticoid receptor and nuclear factor- κ B or activator protein-1: molecular mechanisms for gene repression. *Endocrine Reviews* **24** 488–522.
 Bottner M & Wuttke W 2005 Chronic treatment with low doses of estradiol affects pituitary and thyroid function in young and middle-aged ovariectomized rats. *Biogerontology* **6** 261–269.
 Bottner M, Christoffel J, Rimoldi G & Wuttke W 2006 Effects of long-term treatment with resveratrol and subcutaneous and oral estradiol administration on the pituitary–thyroid-axis. *Experimental and Clinical Endocrinology and Diabetes* **114** 82–90.
 Boyes J, Byfield P, Nakatani Y & Ogryzko V 1998 Regulation of activity of the transcription factor GATA-1 by acetylation. *Nature* **396** 594–598.
 Charles MA, Saunders TL, Wood WM, Owens K, Parlow AF, Camper SA, Ridgway EC & Gordon DF 2006 Pituitary-specific Gata2 knockout: effects on gonadotrope and thyrotrope function. *Molecular Endocrinology* **20** 1366–1377.
 Chuang FM, West BL, Baxter JD & Schaufele F 1997 Activities in Pit-1 determine whether receptor interacting protein 140 activates or inhibits Pit-1/nuclear receptor transcriptional synergy. *Molecular Endocrinology* **11** 1332–1341.
 Coulthard VH, Matsuda S & Heery DM 2003 An extended LXXLL motif sequence determines the nuclear receptor binding specificity of TRAP220. *Journal of Biological Chemistry* **278** 10942–10951.
 Crawford SE, Qi C, Misra P, Stellmach V, Rao MS, Engel JD, Zhu Y & Reddy JK 2002 Defects of the heart, eye, and megakaryocytes in peroxisome proliferator activator receptor-binding protein (PBP) null embryos implicate GATA family of transcription factors. *Journal of Biological Chemistry* **277** 3585–3592.
 Dasen JS, O'Connell SM, Flynn SE, Treier M, Gleiberman AS, Szeto DP, Hooshmand F, Aggarwal AK & Rosenfeld MG 1999 Reciprocal interactions of Pit1 and GATA2 mediate signaling gradient-induced determination of pituitary cell types. *Cell* **97** 587–598.
 Ferreira R, Ohneda K, Yamamoto M & Philipsen S 2005 GATA1 function, a paradigm for transcription factors in hematopoiesis. *Molecular and Cellular Biology* **25** 1215–1227.
 Franklyn JA, Wood DF, Balfour NJ, Ramsden DB, Docherty K & Sheppard MC 1987 Modulation by oestrogen of thyroid hormone effects on thyrotrophin gene expression. *Journal of Endocrinology* **115** 53–59.
 Furlanetto TW, Nguyen LQ & Jameson JL 1999 Estradiol increases proliferation and down-regulates the sodium/iodide symporter gene in FRTL-5 cells. *Endocrinology* **140** 5705–5711.
 Gittoes NJ, McCabe CJ, Verhaeg J, Sheppard MC & Franklyn JA 1997 Thyroid hormone and estrogen receptor expression in normal pituitary and nonfunctioning tumors of the anterior pituitary. *Journal of Clinical Endocrinology and Metabolism* **82** 1960–1967.
 Gordon DF, Lewis SR, Haugen BR, James RA, McDermott MT, Wood WM & Ridgway EC 1997 Pit-1 and GATA-2 interact and functionally cooperate to activate the thyrotropin beta-subunit promoter. *Journal of Biological Chemistry* **272** 24339–24347.
 Gordon DF, Woodmansee WW, Black JN, Dowding JM, Bendrick-Pearl J, Wood WM & Ridgway EC 2002 Domains of Pit-1 required for transcriptional synergy with GATA-2 on the TSH beta gene. *Molecular and Cellular Endocrinology* **196** 53–66.

- Gordon DF, Tucker EA, Tundwal K, Hall H, Wood WM & Ridgway EC 2006 MED220/thyroid receptor-associated protein 220 functions as a transcriptional coactivator with Pit-1 and GATA-2 on the thyrotropin- β promoter in thyrotropes. *Molecular Endocrinology* **20** 1073–1089.
- Gothé S, Wang Z, Ng L, Kindblom JM, Barros AC, Ohlsson C, Vennstrom B & Forrest D 1999 Mice devoid of all known thyroid hormone receptors are viable but exhibit disorders of the pituitary–thyroid axis, growth, and bone maturation. *Genes and Development* **13** 1329–1341.
- Gross HA, Appleman MD Jr & Nicoloff JT 1971 Effect of biologically active steroids on thyroid function in man. *Journal of Clinical Endocrinology and Metabolism* **33** 242–248.
- Haugen BR, McDermott MT, Gordon DF, Rupp CL, Wood WM & Ridgway EC 1996 Determinants of thyrotrope-specific thyrotropin β promoter activation. Cooperation of Pit-1 with another factor. *Journal of Biological Chemistry* **271** 385–389.
- Hayakawa F, Towatari M, Ozawa Y, Tomita A, Privalsky ML & Saito H 2004 Functional regulation of GATA-2 by acetylation. *Journal of Leukocyte Biology* **75** 529–540.
- Heck S, Kullmann M, Gast A, Ponta H, Rahmsdorf HJ, Herrlich P & Cato AC 1994 A distinct modulating domain in glucocorticoid receptor monomers in the repression of activity of the transcription factor AP-1. *EMBO Journal* **13** 4087–4095.
- Herrlich P 2001 Cross-talk between glucocorticoid receptor and AP-1. *Oncogene* **20** 2465–2475.
- Hollowell JG, Staehling NW, Flanders WD, Hannon WH, Gunter EW, Spencer CA & Braverman LE 2002 Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). *Journal of Clinical Endocrinology and Metabolism* **87** 489–499.
- Ito M & Roeder RG 2001 The TRAP/SMCC/mediator complex and thyroid hormone receptor function. *Trends in Endocrinology and Metabolism* **12** 127–134.
- Ito M, Yuan CX, Okano HJ, Darnell RB & Roeder RG 2000 Involvement of the TRAP220 component of the TRAP/SMCC coactivator complex in embryonic development and thyroid hormone action. *Molecular Cell* **5** 683–693.
- Kalaitzidis D & Gilmore TD 2005 Transcription factor cross-talk: the estrogen receptor and NF- κ B. *Trends in Endocrinology and Metabolism* **16** 46–52.
- Kawai K, Sasaki S, Morita H, Ito T, Suzuki S, Misawa H & Nakamura H 2004 Unliganded thyroid hormone receptor- β 1 represses liver X receptor α /oxysterol-dependent transactivation. *Endocrinology* **145** 5515–5524.
- Klinge CM, Bodenner DL, Desai D, Niles RM & Traish AM 1997 Binding of type II nuclear receptors and estrogen receptor to full and half-site estrogen response elements *in vitro*. *Nucleic Acids Research* **25** 1903–1912.
- Kobayashi Y, Kitamoto T, Masuhiro Y, Watanabe M, Kase T, Metzger D, Yanagisawa J & Kato S 2000 p300 mediates functional synergism between AF-1 and AF-2 of estrogen receptor α and β by interacting directly with the N-terminal A/B domains. *Journal of Biological Chemistry* **275** 15645–15651.
- Kraus WL, McInerney EM & Katzenellenbogen BS 1995 Ligand-dependent, transcriptionally productive association of the amino- and carboxyl-terminal regions of a steroid hormone nuclear receptor. *PNAS* **92** 12314–12318.
- Kuiper GG, Enmark E, Pelto-Huikko M, Nilsson S & Gustafsson JA 1996 Cloning of a novel receptor expressed in rat prostate and ovary. *PNAS* **93** 5925–5930.
- Lavinsky RM, Jepsen K, Heinzl T, Torchia J, Mullen TM, Schiff R, Del-Rio AL, Ricote M, Ngo S, Gemsch J *et al.* 1998 Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes. *PNAS* **95** 2920–2925.
- Leong H, Sloan JR, Nash PD & Greene GL 2005 Recruitment of histone deacetylase 4 to the N-terminal region of estrogen receptor α . *Molecular Endocrinology* **19** 2930–2942.
- Lima LP, Barros IA, Lisboa PC, Araujo RL, Silva AC, Rosenthal D, Ferreira AC & Carvalho DP 2006 Estrogen effects on thyroid iodide uptake and thyroperoxidase activity in normal and ovariectomized rats. *Steroids* **71** 653–659.
- Lisboa PC, Curty FH, Moreira RM, Oliveira KJ & Pazos-Moura CC 2001 Sex steroids modulate rat anterior pituitary and liver iodothyronine deiodinase activities. *Hormone and Metabolic Research* **33** 532–535.
- Liu J & Cui S 2005 Ontogeny of estrogen receptor (ER) α and its co-localization with pituitary hormones in the pituitary gland of chick embryos. *Cell and Tissue Research* **320** 235–242.
- Maia AL, Harney JW & Larsen PR 1996 Is there a negative TRE in the luciferase reporter cDNA? *Thyroid* **6** 325–328.
- Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K, Blumberg B, Kastner P, Mark M, Chambon P *et al.* 1995 The nuclear receptor superfamily: the second decade. *Cell* **83** 835–839.
- Mariotti S, Barbesino G, Caturegli P, Bartalena L, Sansoni P, Fagnoni F, Monti D, Fagiolo U, Franceschi C & Pinchera A 1993 Complex alteration of thyroid function in healthy centenarians. *Journal of Clinical Endocrinology and Metabolism* **77** 1130–1134.
- Matsushita A, Sasaki S, Kashiwabara Y, Nagayama K, Ohba K, Iwaki H, Misawa H, Ishizuka K & Nakamura H 2007 Essential role of GATA2 in the negative regulation of thyrotropin β gene by thyroid hormone and its receptors. *Molecular Endocrinology* **21** 865–884.
- McInerney EM, Weis KE, Sun J, Mosselman S & Katzenellenbogen BS 1998 Transcription activation by the human estrogen receptor subtype β (ER β) studied with ER β and ER α receptor chimeras. *Endocrinology* **139** 4513–4522.
- McKay LI & Cidlowski JA 1999 Molecular control of immune/inflammatory responses: interactions between nuclear factor- κ B and steroid receptor-signaling pathways. *Endocrine Reviews* **20** 435–459.
- Metivier R, Petit FG, Valotaire Y & Pakdel F 2000 Function of N-terminal transactivation domain of the estrogen receptor requires a potential α -helical structure and is negatively regulated by the A domain. *Molecular Endocrinology* **14** 1849–1871.
- Metivier R, Penot G, Flouriot G & Pakdel F 2001 Synergism between ER α transactivation function 1 (AF-1) and AF-2 mediated by steroid receptor coactivator protein-1: requirement for the AF-1 α -helical core and for a direct interaction between the N- and C-terminal domains. *Molecular Endocrinology* **15** 1953–1970.
- Nakano K, Matsushita A, Sasaki S, Misawa H, Nishiyama K, Kashiwabara Y & Nakamura H 2004 Thyroid-hormone-dependent negative regulation of thyrotropin β gene by thyroid hormone receptors: study with a new experimental system using CV1 cells. *Biochemical Journal* **378** 549–557.
- Nissen RM & Yamamoto KR 2000 The glucocorticoid receptor inhibits NF κ B by interfering with serine-2 phosphorylation of the RNA polymerase II carboxy-terminal domain. *Genes and Development* **14** 2314–2329.
- Norris JD, Fan D, Sherk A & McDonnell DP 2002 A negative coregulator for the human ER. *Molecular Endocrinology* **16** 459–468.
- Nowakowski BE & Maurer RA 1994 Multiple Pit-1-binding sites facilitate estrogen responsiveness of the prolactin gene. *Molecular Endocrinology* **8** 1742–1749.
- Ozawa Y, Towatari M, Tsuzuki S, Hayakawa F, Maeda T, Miyata Y, Tanimoto M & Saito H 2001 Histone deacetylase 3 associates with and represses the transcription factor GATA-2. *Blood* **98** 2116–2123.
- Pelletier G, Labrie C & Labrie F 2000 Localization of oestrogen receptor α , oestrogen receptor β and androgen receptors in the rat reproductive organs. *Journal of Endocrinology* **165** 359–370.
- Perissi V & Rosenfeld MG 2005 Controlling nuclear receptors: the circular logic of cofactor cycles. *Nature Reviews. Molecular Cell Biology* **6** 542–554.
- Pernasetti F, Caccavelli L, Van de Weerd C, Martial JA & Muller M 1997 Thyroid hormone inhibits the human prolactin gene promoter by interfering with activating protein-1 and estrogen stimulations. *Molecular Endocrinology* **11** 986–996.
- Sasaki S, Nakamura H, Tagami T, Miyoshi Y & Nakao K 1995 Functional properties of a mutant T₃ receptor β (R338W) identified in a subject with pituitary resistance to thyroid hormone. *Molecular and Cellular Endocrinology* **113** 109–117.
- Sasaki S, Lesoon-Wood LA, Dey A, Kuwata T, Weintraub BD, Humphrey G, Yang WM, Seto E, Yen PM, Howard BH *et al.* 1999 Ligand-induced recruitment of a histone deacetylase in the negative-feedback regulation of the thyrotropin β gene. *EMBO Journal* **18** 5389–5398.

- Schaufele F 1999 Regulation of estrogen receptor activation of the prolactin enhancer/promoter by antagonistic activation function-2-interacting proteins. *Molecular Endocrinology* **13** 935–945.
- Scott RE, Wu-Peng XS, Yen PM, Chin WW & Pfaff DW 1997 Interactions of estrogen- and thyroid hormone receptors on a progesterone receptor estrogen response element (ERE) sequence: a comparison with the vitellogenin A2 consensus ERE. *Molecular Endocrinology* **11** 1581–1592.
- Scully KM, Gleiberman AS, Lindzey J, Lubahn DB, Korach KS & Rosenfeld MG 1997 Role of estrogen receptor- α in the anterior pituitary gland. *Molecular Endocrinology* **11** 674–681.
- Sekulic M, Lovren M & Milosevic V 1998 Immunoreactive TSH cells in the pituitary of female middle-aged rats after treatment with estradiol or calcium. *Acta Histochemica* **100** 185–191.
- Sjoberg M & Vennstrom B 1995 Ligand-dependent and -independent transactivation by thyroid hormone receptor beta 2 is determined by the structure of the hormone response element. *Molecular and Cellular Biology* **15** 4718–4726.
- Sosic-Jurjevic B, Filipovic B, Milosevic V, Nestorovic N, Manojlovic-Stojanowski M, Brkic B & Sekulic M 2005 Chronic estradiol exposure modulates thyroid structure and decreases T₄ and T₃ serum levels in middle-aged female rats. *Hormone Research* **63** 48–54.
- Stefaneanu L, Kovacs K, Horvath E, Lloyd RV, Buchfelder M, Fahlbusch R & Smyth H 1994 *In situ* hybridization study of estrogen receptor messenger ribonucleic acid in human adenohypophyseal cells and pituitary adenomas. *Journal of Clinical Endocrinology and Metabolism* **78** 83–88.
- Steger DJ, Hecht JH & Mellon PL 1994 GATA-binding proteins regulate the human gonadotropin α -subunit gene in the placenta and pituitary gland. *Molecular and Cellular Biology* **14** 5592–5602.
- Stumpf M, Waskow C, Krotschel M, van Essen D, Rodriguez P, Zhang X, Guyot B, Roeder RG & Borggreffe T 2006 The mediator complex functions as a coactivator for GATA-1 in erythropoiesis via subunit Med1/TRAP220. *PNAS* **103** 18504–18509.
- Surks MI & Hollowell JG 2007 Age-specific distribution of serum thyrotropin and antithyroid antibodies in the US population: implications for the prevalence of subclinical hypothyroidism. *Journal of Clinical Endocrinology and Metabolism* **92** 4575–4582.
- Surks MI & Sievert R 1995 Drugs and thyroid function. *New England Journal of Medicine* **333** 1688–1694.
- Tao Y, Williams-Skipk C & Scheinman RI 2001 Mapping of glucocorticoid receptor DNA binding domain surfaces contributing to transrepression of NF- κ B and induction of apoptosis. *Journal of Biological Chemistry* **276** 2329–2332.
- Tillman JB, Crone DE, Kim HS, Sprung CN & Spindler SR 1993 Promoter independent down-regulation of the firefly luciferase gene by T₃ and T₃ receptor in CV1 cells. *Molecular and Cellular Endocrinology* **95** 101–109.
- Umesono K & Evans RM 1989 Determinants of target gene specificity for steroid/thyroid hormone receptors. *Cell* **57** 1139–1146.
- Vasudevan N, Koibuchi N, Chin WW & Pfaff DW 2001a Differential crosstalk between estrogen receptor (ER) α and ER β and the thyroid hormone receptor isoforms results in flexible regulation of the consensus ERE. *Brain Research. Molecular Brain Research* **95** 9–17.
- Vasudevan N, Zhu YS, Daniel S, Koibuchi N, Chin WW & Pfaff DW 2001b Crosstalk between oestrogen receptors and thyroid hormone receptor isoforms results in differential regulation of the preproenkephalin gene. *Journal of Neuroendocrinology* **13** 779–790.
- Vasudevan N, Ogawa S & Pfaff DW 2002 Estrogen and thyroid hormone receptor interactions: physiological flexibility by molecular specificity. *Physiological Reviews* **82** 923–944.
- Wasco EC, Martinez E, Grant KS, St Germain EA, St Germain DL & Galton VA 2003 Determinants of iodothyronine deiodinase activities in rodent uterus. *Endocrinology* **144** 4253–4261.
- Webb P, Nguyen P, Shinsako J, Anderson C, Feng W, Nguyen MP, Chen D, Huang SM, Subramanian S, McKinerney E *et al.* 1998 Estrogen receptor activation function 1 works by binding p160 coactivator proteins. *Molecular Endocrinology* **12** 1605–1618.
- Wondisford FE 1996 Factors that control thyroid function: thyrotropin. In *Werner and Ingbar's The Thyroid Seventh Edition*, pp 190–207. Eds LE Braverman & RD Utiger. Philadelphia, USA: Lippincott-Raven Publishers.
- Wondisford FE, Farr EA, Radovick S, Steinfeldler HJ, Moates JM, McClaskey JH & Weintraub BD 1989 Thyroid hormone inhibition of human thyrotropin beta-subunit gene expression is mediated by a cis-acting element located in the first exon. *Journal of Biological Chemistry* **264** 14601–14604.
- Wood WM, Ocran KW, Kao MY, Gordon DF, Alexander LM, Gutierrez-Hartmann A & Ridgway EC 1990 Protein factors in thyrotropic tumor nuclear extracts bind to a region of the mouse thyrotropin beta-subunit promoter essential for expression in thyrotropes. *Molecular Endocrinology* **4** 1897–1904.
- Yang Z & Privalsky ML 2001 Isoform-specific transcriptional regulation by thyroid hormone receptors: hormone-independent activation operates through a steroid receptor mode of co-activator interaction. *Molecular Endocrinology* **15** 1170–1185.
- Yi P, Bhagat S, Hilf R, Bambara RA & Muiyan M 2002 Differences in the abilities of estrogen receptors to integrate activation functions are critical for subtype-specific transcriptional responses. *Molecular Endocrinology* **16** 1810–1827.
- Ying C, Lin DH, Sarkar DK & Chen TT 1999 Interaction between estrogen receptor and Pit-1 protein is influenced by estrogen in pituitary cells. *Journal of Steroid Biochemistry and Molecular Biology* **68** 145–152.
- Yuan CX, Ito M, Fondell JD, Fu ZY & Roeder RG 1998 The TRAP220 component of a thyroid hormone receptor-associated protein (TRAP) coactivator complex interacts directly with nuclear receptors in a ligand-dependent fashion. *PNAS* **95** 7939–7944.
- Yusta B, Alarid ET, Gordon DF, Ridgway EC & Mellon PL 1998 The thyrotropin beta-subunit gene is repressed by thyroid hormone in a novel thyrotrope cell line, mouse T alphaT1 cells. *Endocrinology* **139** 4476–4482.
- Zhang X, Jeyakumar M & Bagchi MK 1996 Ligand-dependent cross-talk between steroid and thyroid hormone receptors. Evidence for common transcriptional coactivator(s). *Journal of Biological Chemistry* **271** 14825–14833.
- Zhang X, Krutchinsky A, Fukuda A, Chen W, Yamamura S, Chait BT & Roeder RG 2005 MED1/TRAP220 exists predominantly in a TRAP/mediator subpopulation enriched in RNA polymerase II and is required for ER-mediated transcription. *Molecular Cell* **19** 89–100.
- Zhu YS, Yen PM, Chin WW & Pfaff DW 1996 Estrogen and thyroid hormone interaction on regulation of gene expression. *PNAS* **93** 12587–12592.

Received in final form 11 July 2008

Accepted 22 July 2008

Made available online as an Accepted Preprint
23 July 2008